Clinical trial · Interventional
R2 in the Treatment of Follicular Lymphoma
R2 in the Treatment of Follicular Lymphoma Grade 1-3A
NCT03715309CI-TRIAL-00039370unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lenalidomide Based Immunotherapy in the Treatment of FL
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Revlimid | Drug | Lenalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Revlimd
- interventionNames
- Drug: Revlimid
Primary outcomes (1)
- measure
- CR
- timeFrame
- 12 weeks
- description
- Complete response rate
Secondary outcomes (3)
- measure
- PFS
- timeFrame
- 1 year
- description
- Progression free survival rate
- measure
- OS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Patients diagnose as de novo or relapse refractory FL grade 1-3A . No history of stem cell transplantation. Written informed consent. Exclusion Criteria: Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study. Clinically significant active infection. Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures. Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment. Patients who are pregnant or breast-feeding. HIV infection.
References
Publications (1)
- DERIVEDZheng Z, Wang JB, Sun R, Wang N, Weng XQ, Xu TY, Fu D, Feng Y, Xu PP, Cheng S, Wang L, Zhao Y, Qu B, Huang CX, Zhao WL. Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma. Signal Transduct Target Ther. 2025 Jan 20;10(1):29. doi: 10.1038/s41392-024-02105-7. PMID 39828715